Free Newsletter
Managed care expects to broaden Crestor use
Free newsletter via e-mail
Tools
More good news for AstraZeneca's Crestor: Managed care pharmacy directors are saying they'll pay for the statin for healthy patients without high LDL cholesterol, but with elevated high sensitivity C-reactive protein, after the Jupiter trial found outcomes benefits from Crestor use in those patients. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: